Filgrastim Completed Phase 1 / 2 Trials for Hodgkins Disease (HD) / Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00392691Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT01421173Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT00058292Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma